Health-related Quality of Life 3 Years After High-dose Intensity-modulated Radiotherapy with Gold Fiducial Marker-based Position Verification
Affiliations
Objective: To evaluate the change in quality of life (QoL) 3 years after high-dose intensity-modulated radiotherapy (IMRT) using gold fiducial marker-based position verification in patients with locally advanced prostate cancer.
Patients And Methods: Between October 2003 and November 2004, 95 patients with locally advanced prostate cancer were treated with 76 Gy IMRT with gold-fiducial marker-based position verification. Before treatment (baseline) and 1, 6 and 36 months after RT the QoL was measured using the RAND-36, the European Organization for Research and Treatment of Cancer (EORTC) core questionnaire (QLQ-C30(+3)) and the prostate tumour-specific module (EORTC QLQ-PR25). Changes in QoL with time of > or =10 points were considered clinically relevant.
Results: After 3 years there was a statistically significant improvement in QoL for emotional role restriction and functioning, change in health, mental health and insomnia, compared with baseline. Emotional role restriction increased by >10 points and was therefore clinically relevant, while all other differences were of <10 points. There was a statistically significant deterioration of QoL after 3 years in physical and cognitive functioning, bowel symptoms/function and sexual activity. Only the sexual activity QoL score changed by 12 points and was therefore the only meaningful deterioration in QoL at 3 years after treatment.
Conclusion: IMRT and accurate position verification provide the possibility to deliver a high irradiation dose to the prostate without clinically relevant deterioration in long-term QoL, except for a persistent decrease in sexual activity score.
Maggio A, Rancati T, Gatti M, Cante D, Avuzzi B, Bianconi C Curr Oncol. 2024; 31(2):839-848.
PMID: 38392056 PMC: 10887595. DOI: 10.3390/curroncol31020062.
Goineau A, Campion L, dAillieres B, Vie B, Ghesquiere A, Bera G PLoS One. 2018; 13(4):e0194173.
PMID: 29630602 PMC: 5890970. DOI: 10.1371/journal.pone.0194173.
Patient-Reported Physical Function Measures in Cancer Clinical Trials.
Atkinson T, Stover A, Storfer D, Saracino R, DAgostino T, Pergolizzi D Epidemiol Rev. 2017; 39(1):59-70.
PMID: 28453627 PMC: 5858035. DOI: 10.1093/epirev/mxx008.
Zhou E, Nekhlyudov L, Bober S Transl Androl Urol. 2016; 4(2):218-31.
PMID: 26816826 PMC: 4708119. DOI: 10.3978/j.issn.2223-4683.2014.11.07.
Quality of life in patients with prostate cancer treated with radical image-guided radiotherapy.
Majewski W, Tabor K, Prokop E, Kulik R Contemp Oncol (Pozn). 2014; 18(4):285-9.
PMID: 25258588 PMC: 4171474. DOI: 10.5114/wo.2014.44097.